CY1124148T1 - Θεραπευτικοι παραγοντες για τη θεραπευτικη αγωγη ασθενειων που συνδεονται με ανεπιθυμητο κυτταρικο πολλαπλασιασμο - Google Patents

Θεραπευτικοι παραγοντες για τη θεραπευτικη αγωγη ασθενειων που συνδεονται με ανεπιθυμητο κυτταρικο πολλαπλασιασμο

Info

Publication number
CY1124148T1
CY1124148T1 CY20211100232T CY211100232T CY1124148T1 CY 1124148 T1 CY1124148 T1 CY 1124148T1 CY 20211100232 T CY20211100232 T CY 20211100232T CY 211100232 T CY211100232 T CY 211100232T CY 1124148 T1 CY1124148 T1 CY 1124148T1
Authority
CY
Cyprus
Prior art keywords
cell proliferation
diseases associated
treatment
therapeutic agents
undesirable cell
Prior art date
Application number
CY20211100232T
Other languages
English (en)
Inventor
Silvia PEÑUELAS PRIETO
José BASELGA TORRES
Joan SEOANE SUÁREZ
Original Assignee
Fundació Privada Institució Catalana De Recerca I Estudis Avançats
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Privada Institució Catalana De Recerca I Estudis Avançats filed Critical Fundació Privada Institució Catalana De Recerca I Estudis Avançats
Publication of CY1124148T1 publication Critical patent/CY1124148T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)

Abstract

Η εφεύρεση βασίζεται στην παρατήρηση ότι η LIF είναι ικανή να ενεργοποιεί την αυτοανανέωση των βλαστικών κυττάρων όγκου στον καρκίνο, συγκεκριμένα τα γλοιώματα, κάτι το οποίο υποδεικνύει ότι η αναστολή της LIF, και γενικά των κυτοκινών τύπου IL-6, μπορεί να χρησιμοποιηθεί σε θεραπευτικές συνθέσεις, για τη θεραπευτική αγωγή ασθενειών που σχετίζονται με ανεπιθύμητο πολλαπλασιασμό. Η εφεύρεση αναφέρεται επίσης σε μια μέθοδο για την ταυτοποίηση ενώσεων ικανών να εμποδίζουν/αναστέλλουν τον πολλαπλασιασμό των βλαστικών κυττάρων, και σε μια in vitro μέθοδο για τη διάγνωση ασθενειών που σχετίζονται με ανεπιθύμητο κυτταρικό πολλαπλασιασμό σε ένα υποκείμενο ή για τον προσδιορισμό της προδιάθεσης ενός υποκειμένου να πάσχει από την εν λόγω ασθένεια που σχετίζεται με ανεπιθύμητο κυτταρικό πολλαπλασιασμό, ή για πρόγνωση του μέσου προσδόκιμου ζωής των υποκειμένων που πάσχουν από τους εν λόγω όγκους.
CY20211100232T 2009-04-03 2021-03-18 Θεραπευτικοι παραγοντες για τη θεραπευτικη αγωγη ασθενειων που συνδεονται με ανεπιθυμητο κυτταρικο πολλαπλασιασμο CY1124148T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200900928A ES2363358B1 (es) 2009-04-03 2009-04-03 Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP10713619A EP2414394A2 (en) 2009-04-03 2010-04-06 Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
PCT/EP2010/054499 WO2010115868A2 (en) 2009-04-03 2010-04-06 Therapeutic agents for the treatment of diseases associated with undesired cell proliferation

Publications (1)

Publication Number Publication Date
CY1124148T1 true CY1124148T1 (el) 2022-05-27

Family

ID=42342718

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100232T CY1124148T1 (el) 2009-04-03 2021-03-18 Θεραπευτικοι παραγοντες για τη θεραπευτικη αγωγη ασθενειων που συνδεονται με ανεπιθυμητο κυτταρικο πολλαπλασιασμο

Country Status (23)

Country Link
US (3) US10100112B2 (el)
EP (2) EP2414394A2 (el)
JP (5) JP6207836B2 (el)
KR (6) KR20190093691A (el)
CN (2) CN107964043A (el)
AU (1) AU2010233791B2 (el)
BR (1) BRPI1015369A2 (el)
CA (1) CA2757680C (el)
CY (1) CY1124148T1 (el)
DK (1) DK3045474T3 (el)
EA (1) EA201101450A1 (el)
ES (2) ES2363358B1 (el)
HR (1) HRP20210352T1 (el)
HU (1) HUE054196T2 (el)
IL (1) IL215467A (el)
LT (1) LT3045474T (el)
MX (1) MX336903B (el)
PL (1) PL3045474T3 (el)
PT (1) PT3045474T (el)
SG (2) SG175032A1 (el)
SI (1) SI3045474T1 (el)
WO (1) WO2010115868A2 (el)
ZA (1) ZA201107215B (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5189977B2 (ja) * 2005-07-19 2013-04-24 ステムジェン ソシエタ ペル アチオニ Ｌｉｆおよびｂｍｐによる腫瘍性幹細胞の潜在的腫瘍形成能力の抑制
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
JP2015071566A (ja) * 2013-10-03 2015-04-16 住友ベークライト株式会社 Ｆｇｆ４遺伝子増幅腫瘍の医薬組成物
AU2015228386A1 (en) * 2014-03-11 2016-09-22 Godavari Biorefineries Limited Cancer stem cell targeting compounds
CN112494646A (zh) * 2014-06-30 2021-03-16 阿尔托生物科学有限公司 基于il-15的分子及其方法和用途
WO2016040657A1 (en) * 2014-09-10 2016-03-17 The Regents Of The University Of California TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES
EP3067422A3 (en) * 2015-03-13 2016-11-30 Sabanci Üniversitesi Ct-1 inhibitors
MX2017012068A (es) 2015-03-23 2018-06-28 Evestra Inc Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos.
EP3173483A1 (en) 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
BR112019012691A2 (pt) 2016-12-19 2019-11-19 Fundacio Privada Inst Catalana De Recerca I Estudis Avancats anticorpos contra a lif e seus usos
KR20210008514A (ko) * 2018-05-14 2021-01-22 메디뮨 리미티드 Lif에 대한 항체 및 이의 투여 형태
CA3103763A1 (en) * 2018-06-18 2019-12-26 Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats Methods for improving response to anti-lif antibody treatment in individuals with cancer
CA3103369A1 (en) * 2018-06-18 2019-12-26 Medimmune Limited Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer
WO2020056349A2 (en) * 2018-09-13 2020-03-19 Evestra, Inc. Lif/lifr antagonist oncology and nonmalignant diseases
JPWO2020213665A1 (el) * 2019-04-17 2020-10-22
CN111020030A (zh) * 2019-12-03 2020-04-17 中山大学 一种骨肉瘤干细胞标志物及其应用、试剂盒
EP3988116A1 (en) * 2020-10-23 2022-04-27 Consejo Superior De Investigaciones Científicas (CSIC) Methods and compositions for the treatment of hematologic malignancies

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
RO114469B1 (ro) 1987-12-15 1999-04-30 Gene Shears Pty Ltd Compus oligoribonucleotidic, procedeu de preparare si metoda de inactivare
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
GB9004890D0 (en) * 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
JPH05304986A (ja) * 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
GB9413316D0 (en) 1994-07-01 1994-08-24 Cancer Res Campaign Tech Novel proteins
US6251588B1 (en) 1998-02-10 2001-06-26 Agilent Technologies, Inc. Method for evaluating oligonucleotide probe sequences
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
PL200919B1 (pl) * 1999-02-12 2009-02-27 Lexigen Pharm Corp Zastosowanie kompozycji czynnika hamującego angiogenezę i czynnika przeciwnowotworowego, kompozycja terapeutyczna do leczenia nowotworów i zestaw do traktowania komórki nowotworowej
US6110462A (en) 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
WO2004016758A2 (en) * 2002-08-15 2004-02-26 Genzyme Corporation Brain endothelial cell expression patterns
US20060078533A1 (en) * 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US20040248158A1 (en) * 2003-01-28 2004-12-09 Loughran Thomas P Differentially expressed genes in large granular lymphocyte leukemia
WO2005030803A1 (en) * 2003-09-29 2005-04-07 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
AU2005248147A1 (en) 2004-05-11 2005-12-08 Alphagen Co., Ltd. Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
KR20110068987A (ko) * 2008-08-29 2011-06-22 제넨테크, 인크. Ｖｅｇｆ-비의존적 종양의 진단 및 치료
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof

Also Published As

Publication number Publication date
CA2757680A1 (en) 2010-10-14
HRP20210352T1 (hr) 2021-05-28
KR20200078668A (ko) 2020-07-01
LT3045474T (lt) 2021-05-10
EP2414394A2 (en) 2012-02-08
ES2363358B1 (es) 2012-06-21
DK3045474T3 (da) 2021-03-22
EP3045474B1 (en) 2021-01-13
SG10202010568RA (en) 2020-11-27
ES2864639T3 (es) 2021-10-14
AU2010233791B2 (en) 2016-01-21
KR20120100703A (ko) 2012-09-12
CN107964043A (zh) 2018-04-27
KR20180079470A (ko) 2018-07-10
KR20170121319A (ko) 2017-11-01
PL3045474T3 (pl) 2021-08-09
SG175032A1 (en) 2011-11-28
US20190211095A1 (en) 2019-07-11
US10100112B2 (en) 2018-10-16
KR102373754B1 (ko) 2022-03-15
EA201101450A1 (ru) 2012-04-30
JP2016040255A (ja) 2016-03-24
EP3045474A3 (en) 2016-09-28
MX2011010425A (es) 2012-03-06
EP3045474A2 (en) 2016-07-20
KR20220035978A (ko) 2022-03-22
PT3045474T (pt) 2021-03-22
IL215467A (en) 2016-06-30
SI3045474T1 (sl) 2021-07-30
AU2010233791A1 (en) 2011-11-03
JP2012522756A (ja) 2012-09-27
JP2019006784A (ja) 2019-01-17
BRPI1015369A2 (pt) 2021-06-29
JP6207836B2 (ja) 2017-10-04
US20120114671A1 (en) 2012-05-10
CA2757680C (en) 2021-11-02
IL215467A0 (en) 2011-12-29
ES2363358A1 (es) 2011-08-01
WO2010115868A2 (en) 2010-10-14
MX336903B (es) 2016-02-04
KR20190093691A (ko) 2019-08-09
HUE054196T2 (hu) 2021-08-30
CN102574918A (zh) 2012-07-11
JP7197665B2 (ja) 2022-12-27
JP2022031742A (ja) 2022-02-22
WO2010115868A3 (en) 2011-02-03
US20200385455A1 (en) 2020-12-10
ZA201107215B (en) 2012-12-27
JP2020090522A (ja) 2020-06-11

Similar Documents

Publication Publication Date Title
CY1124148T1 (el) Θεραπευτικοι παραγοντες για τη θεραπευτικη αγωγη ασθενειων που συνδεονται με ανεπιθυμητο κυτταρικο πολλαπλασιασμο
CY1119451T1 (el) Αντισωμα που αναγνωριζει τον ανθρωπινο ανασταλτικο παραγοντα λευχαιμιας (lif) και η χρηση των anti-lif αντισωματων στη θεραπεια παθησεων που συνδεονται με ανεπιθυμητο κυτταρικο πολλαπλασιασμο
CY1117604T1 (el) Μια νεα ομαδα αναστολεων του μονοπατιου stat3 και αναστολεων του μονοπατιου καρκινικων βλαστοκυτταρων
CY1126122T1 (el) Αναστολεις πρωτεϊνικης φωσφατασης της τυροσινης
CY1125092T1 (el) Ιατρικη χρηση σχετικα με επεκταση τελομερους
CY1119956T1 (el) Μονοκλωνικα anti-gt468 αντισωματα για θεραπεια καρκiνου
CY1114663T1 (el) 5-ανιλινοϊμιδαζοπυριδινες και μεθοδοι χρησης
CY1119722T1 (el) Δημιουργια και περιγραφη πληρως ανθρωπινων θεραπευτικων αντισωματων λαμβανομενων μεσω hucal gold ειδικων για ανθρωπινό cd38
BR112018010927A2 (pt) anticorpos multiespecíficos
CY1118072T1 (el) Συζευγματα cc-1065 αναλογων και διλειτουργικων αρθρωτων
CR9315A (es) Metodos y sistemas para el diagnostico, pronostico y seleccion del tratamiento de la leucemia
EA200700321A1 (ru) Пиразолзамещённые аминогетероарильные соединения в качестве ингибиторов протеинкиназы
EA201290894A1 (ru) Азетидиновые производные пиперидин-4-ила как ингибиторы jak1
EA201391208A1 (ru) КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ С ПРИМЕНЕНИЕМ ИНГИБИТОРОВ mTOR/JAK
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
CR9365A (es) Compuestos y metodos para la inhibicion de la protein-cinasa raf
ECSP10010510A (es) Compuestos del inhibidor de raf y métodos de uso de los mismos
ATE527385T1 (de) Mit tumoren assoziierte genetische variationen
EA201590724A1 (ru) Prdm14 и fam19a4, молекулярные диагностические маркеры для выявления впч-индуцируемых инвазивных раковых заболеваний и предшествующих им поражений высокой степени
WO2020107002A3 (en) Methods for expansion of natural killer (nk) cell subset and related compositions and methods
RU2014149559A (ru) Селективные ингибиторы недифференцированных клеток
Corvalan et al. Methylation of histone 4’s lysine 20: a critical analysis of the state of the field
UY36200A (es) Conjunto de biomarcadores específicos para diagnóstico no invasivo de cáncer de hígado
BR112015012507A8 (pt) método in vitro de seleção de um indivíduo diagnosticado ou suspeito de ter câncer e uso de um inibidor de telomerase